MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients with metastatic urothelial cancer (mUC) (Alliance A032001)

被引：0
作者：
Gupta, Shilpa
Ballman, Karla V.
Galsky, Matt D.
Morris, Michael J.
Chen, Ronald C.
Chan, Timothy A.
Dercle, Laurent
Wen, Yujia
Sridhar, Srikala S.
Yen, Aihua Edward
Grivas, Petros
Tan, Alan
Baghaie, Shiva
Rosenberg, Jonathan E.
机构：
[1] Cleveland Clin Fdn, Taussig Canc Inst, Cleveland, OH USA
[2] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA
[3] Tisch Canc Inst, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, Div Solid Tumor Oncol, New York, NY USA
[5] Univ Kansas, Kansas City, KS USA
[6] Mem Sloan Kettering Canc Ctr, New York, NY USA
[7] Columbia Univ, New York Presbyterian Hosp, Dept Radiol, Med Ctr, New York, NY USA
[8] Univ Chicago, Chicago, IL USA
[9] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada
[10] Baylor Coll Med, Houston, TX USA
[11] Univ Washington, Seattle, WA USA
[12] Fred Hutchinson Canc Res Ctr, Seattle, WA USA
[13] Premier Onc Hem Assoc, Chicago, IL USA
[14] Alliance Clin Trials Oncol, Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4607
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Real world progression-free survival in patients with advanced or metastatic urothelial cancer treated with first-line platinum-based chemotherapy
    Nikolaidis, Christos
    Li, Chen
    Lee, Chooi
    Mecke, Almut
    Reyes-Rivera, Irmarie
    Schroder, Carsten
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 319 - 319
  • [32] SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC
    Cappuzzo, F.
    Ciuleanu, T.
    Stelmakh, L.
    Cicenas, S.
    Szczesna, A.
    Juhasz, E.
    Gonzalez, E. Esteban
    Molinier, O.
    Klingelschmitt, G.
    Giaccone, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [33] Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy
    Despierre, Evelyn
    Vergote, Ignace
    Anderson, Ryan
    Coens, Corneel
    Katsaros, Dionyssios
    Hirsch, Fred R.
    Boeckx, Bram
    Varella-Garcia, Marileila
    Ferrero, Annamaria
    Ray-Coquard, Isabelle
    Berns, Els M. J. J.
    Casado, Antonio
    Lambrechts, Diether
    Jimeno, Antonio
    TARGETED ONCOLOGY, 2015, 10 (04) : 583 - 596
  • [34] Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy
    Evelyn Despierre
    Ignace Vergote
    Ryan Anderson
    Corneel Coens
    Dionyssios Katsaros
    Fred R. Hirsch
    Bram Boeckx
    Marileila Varella-Garcia
    Annamaria Ferrero
    Isabelle Ray-Coquard
    Els M. J. J. Berns
    Antonio Casado
    Diether Lambrechts
    Antonio Jimeno
    Targeted Oncology, 2015, 10 : 583 - 596
  • [35] Meet-URO 12: A randomized phase II trial of niraparib versus best supportive care (BSC) as maintenance treatment in patients with locally advanced or metastatic urothelial cancer (UC) whose disease did not progress after completion of first-line platinum-based chemotherapy
    Vignani, F.
    Hamzaj, A.
    De Giorgi, U.
    Tambaro, R.
    Basso, U.
    Gamba, T.
    Ermacora, P.
    Santini, D.
    Capacci, S.
    Casadei, C.
    Pignata, S.
    Bimbatti, D.
    Giannatempo, P.
    Atzori, F.
    Cavanna, L.
    Veccia, A.
    Scandurra, G.
    Doni, L.
    Aieta, M.
    Di Maio, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S607 - S607
  • [36] Avelumab Versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Patients With High-Expression Programmed Death-Ligand 1-Positive Metastatic NSCLC: Primary Analysis From the Phase 3 JAVELIN Lung 100 Trial
    Reck, Martin
    Barlesi, Fabrice
    Yang, James Chih-Hsin
    Westeel, Virginie
    Felip, Enriqueta
    Ozguroglu, Mustafa
    Dols, Manuel Cobo
    Sullivan, Richard
    Kowalski, Dariusz M.
    Andric, Zoran
    Lee, Dae Ho
    Sezer, Ahmet
    Hu, Ping
    Wang, XiaoZhe
    von Heydebreck, Anja
    Jacob, Natalia
    Mehr, Keyvan Tadjalli
    Park, Keunchil
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (02) : 297 - 313
  • [37] Trial in progress: A phase II switch maintenance study of live biotherapeutic MRx0518 and avelumab in patients with unresectable locally advanced or metastatic urothelial carcinoma (UC) who did not progress on first-line platinum-containing chemotherapy
    Shah, Amishi Yogesh
    Gao, Jianjun
    Rezazadeh, Arash
    Cole, Suzanne
    Jain, Rohit K.
    Stevenson, Alex
    Fyvie, Gayle
    Gaw, Nina Jane
    Pant, Shubham
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] IMvigor130: A randomized, phase III study evaluating first-line (1L) atezolizumab (atezo) as monotherapy and in combination with platinum-based chemotherapy (chemo) in patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC).
    Galsky, Matt D.
    Grande, Enrique
    Davis, Ian D.
    De Santis, Maria
    Arija, Jose Angel Arranz
    Kikuchi, Eiji
    Mecke, Almut
    Thastrom, Ann Christine
    Bamias, Aristotelis
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [39] A multicenter phase II study of avelumab in patients with locally advanced or metastatic penile cancer (PC) who are unfit for, or have progressed on or after platinum-based chemotherapy: (ALPACA)
    Alqaisi, Husam
    Winquist, Eric
    Mukherjee, Som
    Canil, Christina M.
    Fallah-Rad, Nazanin
    Less, Srikala S. SridharShow
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [40] Erratum to: Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy
    Evelyn Despierre
    Ignace Vergote
    Ryan Anderson
    Corneel Coens
    Dionyssios Katsaros
    Fred R. Hirsch
    Bram Boeckx
    Marileila Varella-Garcia
    Annamaria Ferrero
    Isabelle Ray-Coquard
    John A. Green
    Christopher Steer
    Els M. J. J. Berns
    Antonio Casado
    Diether Lambrechts
    Antonio Jimeno
    Targeted Oncology, 2016, 11 : 429 - 429
12345